-

01:25:20 PM

ELOX Stock News

ELOX - Eloxx Pharmaceuticals Inc

09/19/23 8:00 AM

Nasdaq : ELOX

offeringlow float

Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 380,590 of its

RHEA-AI

neutral

09/18/23 7:00 AM

Nasdaq : ELOX

clinical triallow float

Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome

Highly regarded renal pathologist and transmission electron microscopy (TEM) expert independently confirms previously reported qualitative assessment by Mayo Clinic of TEM biopsy scans All three patients treated with ELX-02 showed a visual improvement in podocyte foot process effacement

RHEA-AI

neutral

09/07/23 9:00 AM

Nasdaq : ELOX

low float

Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013

Investigational New Drug (IND) application submitted to U.S. Food and Drug Administration (FDA) for ELX-02 for the treatment of Alport syndrome with nonsense mutations Rebound in average UPCR 3-months post treatment provides further evidence that proteinuria remission in one out of three patients

RHEA-AI

positive

08/14/23 8:30 AM

Nasdaq : ELOX

earningslow float

Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update

Announced today that all 3 patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot process effacement post-treatment in kidney biopsies assessed by electron microscopy, demonstrating the disease-modifying effect of ELX-02 Announced achievement of remission in one

RHEA-AI

neutral

08/14/23 8:00 AM

Nasdaq : ELOX

clinical triallow float

Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome

All three patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot process effacement post-treatment in kidney biopsies assessed by electron microscopy demonstrating the disease modifying effect of ELX-02 Podocyte foot process effacement is a hallmark of Alport

RHEA-AI

neutral

08/03/23 9:26 AM

Nasdaq : ELOX

low float

Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement

Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it received notice from the Nasdaq Listing Qualifications Panel (the “Hearings Panel”) of The Nasdaq Stock

RHEA-AI

positive

07/10/23 9:00 AM

Nasdaq : ELOX

low float

Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic Benefit

Publication titled “A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer” published in Cancer Research Communications Results suggest that MYC overexpressing cancers can be targeted by exploiting ribosome

RHEA-AI

neutral

06/28/23 9:00 AM

Nasdaq : ELOX

clinical triallow float

Eloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study Evaluating ELX-02

Alport syndrome is a rare progressive hereditary glomerular kidney disease caused by variants in COL4A and patients have significant unmet medical needs, with no disease modifying treatments currently available Eloxx announced additional results from its Phase 2 ELX-02 trial showing the patient

RHEA-AI

neutral

06/21/23 1:30 PM

Nasdaq : ELOX

conferenceslow float

Eloxx Pharmaceuticals to Host Investor and Analyst Call on Alport Syndrome

RHEA-AI

neutral

06/21/23 9:00 AM

Nasdaq : ELOX

low float

Eloxx Pharmaceuticals Highlights Recent Alport Syndrome Natural History Data Presented at 60th ERA Congress

Data from RaDaR natural history study indicates that Alport syndrome patients with autosomal recessive COL4A4 mutations have severest disease, with a more rapid progression to kidney failure Patient that achieved remission in Eloxx Phase 2 trial had autosomal recessive COL4A4 nonsense mutation

RHEA-AI

neutral

1 2 3 4 5 6 7 Next

ELOX Data

IndustryResearch and Development in Biotechnology
Websitehttps://www.eloxxpharma.com/
Security nameEloxx Pharmaceuticals Inc
SectorProfessional, Scientific, and Technical Services
Tags
- Health Technology
- Biotechnology
CountryUS

About Eloxx Pharmaceuticals Inc

eloxx pharmaceuticals, inc. is a clinical-stage biopharmaceutical company developing novel rna-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. premature stop codons are point mutations that disrupt protein synthesis from messenger rna. as a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. these premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. read-through therapeutic development is focused on extending mrna half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. eloxx’s lead product candidate, elx-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. elx-02 is in the early stages of clin